Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four commercialized molecular tests; PancraGen, an integrated molecular pathology platform used for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts and lesions; ThyGeNEXT, a Next Generation Sequencing based mutation profile that identifies mutations from thyroid nodules that are highly indicative of thyroid cancer when traditional cytology is indeterminate; ThyraMIR, a proprietary, miRNA based classifier that assists physicians in identifying those thyroid nodules least likely to be malignant when traditional cytology is indeterminate; and RespriDx, used for distinguishing lesions in the lung that represent new tumors from those caused by metastases from other organs. The Company also has a development portfolio that includes BarreGEN for Barrettâs Esophagus, a test that enables physicians to identify those patients with this common diagnosis that are most likely to progress to esophageal cancer so intervention can be performed. Interpace Diagnostics was formed in April, 2014 as a Division of PDI, Inc., (created in 1998 as a public company with over 1,000 employees that provided Contract Sales services to pharmaceutical companies.) After the sale of the pharmaceutical contract sales business in December of 2015, Interpace Diagnostics Group became the sole operating company and the name PDI was changed to Interpace Diagnostics Group, Inc. The public company status remained the same (NASDAQ: IDXG). Interpace Diagnostics is an independent molecular diagnostics Company providing services to specialty physicians and medical centers throughout the U.S. and in a limited number of international markets as well. Source
No articles found.
LHC Group, Inc. is a national provider of in-home healthcare services and innovati...
LHC Group, Inc. is a national provider of in-ho...
Armed with cutting-edge technology and MIT science, experienced business and medic...
Armed with cutting-edge technology and MIT scie...
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, ma...
IRIDEX Corporation was founded in 1989 and is a...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...
Iovance Biotherapeutics (formerly traded as Lio...
Cesca is a leading regenerative medicine company that develops, commercializes and...
Cesca is a leading regenerative medicine compan...
Celcuity is a cellular analysis company that is discovering new cancer sub-types a...
Celcuity is a cellular analysis company that is...
Join the National Investor Network and get the latest information with your interests in mind.